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OBJECTIVES This study investigated the prognostic importance of measured peak oxygen intake (V˙O2peak)
in women with known coronary heart disease referred for outpatient cardiac rehabilitation.
BACKGROUND Exercise capacity is a powerful predictor of prognosis in men with known or suspected
coronary disease. Similar findings are described in women, but fewer studies have utilized
measured V˙O2peak, the most accurate measure of exercise capacity.
METHODS A single-center design took data from 2,380 women, age 59.7  9.5 years (1,052 myocardial
infarctions, 620 coronary bypass procedures, and 708 with proven ischemic heart disease),
who underwent cardiorespiratory exercise testing. They were followed for an average of 6.1
 5 years (median 4.5 years, range 0.4 to 25 years) until cardiac and all-cause death.
RESULTS We recorded 95 cardiac deaths and 209 all-cause deaths. Measured V˙O2peak was an
independent predictor of risk, values13 ml/kg/min (3.7 multiples of resting metabolic rate)
conferring a 50% reduction in cardiac mortality (hazard ratio [HR] 0.5, p  0.001).
Considered as a continuous variable, a 1 ml/kg/min advantage in initial V˙O2peak was
associated with a 10% lower cardiac mortality. Adverse predictors were diabetes (HR 2.73, p
 0.0005) and antiarrhythmic therapy (HR 3.93, p  0.0001).
CONCLUSIONS As in men, measured V˙O2peak is a strong independent predictor of cardiac mortality in
women referred for cardiac rehabilitation. (J Am Coll Cardiol 2003;42:2139–43) © 2003
by the American College of Cardiology Foundation
The long-term prognosis of men with known or suspected
coronary artery disease is strongly related to exercise capacity
(1–3). The same relationship has been described in healthy
women (4) and in women with ischemic heart disease
(IHD) (5–8). However, most reports have expressed exer-
cise capacity as a treadmill time or MET value (multiples of
the resting metabolic rate) rather than measured peak
oxygen intake (V˙O2peak), the most accurate measure of
exercise capacity (9). We therefore examined the prognostic
value of measured V˙O2peak in a substantial sample of women
with proven coronary heart disease (CHD).
METHODS
Study population. A total of 2,380 women (1,052 myo-
cardial infarctions [MIs], 620 coronary artery bypass graft
procedures [CABGs], and 708 documented cases of IHD,
including 161 statistically similar patients who underwent a
percutaneous coronary intervention) were referred for exer-
cise testing 13.9  4.1 weeks after the event, procedure, or,
in the case of IHD, diagnosis. Referrals grouped in five-year
intervals were as follows: 1973 to 1977, n  72; 1978 to
1982, n  235; 1983 to 1987, n  394; 1988 to 1992, n 
549; 1993 to 1998, n  1,130.
Follow-up. Health status was obtained from a question-
naire mailed at approximately 12- to 18-month intervals.
Death certificates were examined for decedents resident in
Ontario; for 15 decedents no longer resident in Ontario,
cause of death was determined from information obtained
from a physician, spouse, or other family members.
Cardiorespiratory testing. All patients underwent maxi-
mal cardiorespiratory exercise testing on the cycle ergome-
ter, using the identical protocol we have previously em-
ployed in men (3). Measurements included continuous
electrocardiographic monitoring, resting and exercise blood
pressure, the rating of perceived exertion on the original
Borg scale, and analysis of respiratory gases for V˙O2peak and
ventilatory threshold.
Statistical methods. Data were analyzed using univariate
and multivariate Cox proportional hazard models. Survival
time was defined as the day of the exercise test to cardiac
death, all-cause death, or last contact. The V˙O2peak was
treated both as a continuous variable and then as a binary
variable, with the optimal cutoff point determined by
recursive partitioning (10,11). Hazard ratios (HRs) were
calculated for individual risk factors, agreement between
measured and predicted V˙O2peak assessed using kappa
statistic, and paired comparison made using McNemar’s
chi-square test. Kaplan-Meier survival curves were also
generated. SAS Software version 8.2 (SAS Institute Inc.,
Cary, North Carolina) was used for all statistical analyses.
RESULTS
Clinical and physiologic characteristics. The mean age at
the time of testing was 59.7  9.5 years. We were unable to
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contact 103 patients (4.3% of sample). Patients tended
towards obesity (27% had a body mass index 30; mean
34.4  4.0 kg/m2), and approximately one-half were taking
a platelet inhibitor (most commonly aspirin) or a beta-
blocker (Table 1).
The average V˙O2peak values were typical of those we and
others have reported on postcoronary women in their late
50s (12,13). Complex ventricular arrhythmias, significant
ST-segment depression (0.2 mV), and exertional angina
occurred in 9.1%, 7.7%, and 10.4% of patients, respectively.
The average follow-up time was 6.1  5 years (median
4.5 years, range 0.4 to 25 years). During follow-up, 95
cardiac deaths (59 MI, 23 CABG, 13 IHD) and 209
all-cause deaths (4% and 8.8%, respectively, of the sample)
were recorded. The average time from the exercise test to
cardiac death was 7.3  4.6 years (median 6.8 years) and to
all-cause death 8.3  3.2 years (median 7.7 years).
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CHD  coronary heart disease
CI  confidence interval
HR  hazard ratio
IHD  ischemic heart disease
METs  multiples of resting metabolic rate
MI  myocardial infarction
V˙O2peak  peak oxygen intake
Table 1. Demographic and Clinical Characteristics of All Subjects According to Diagnosis
Variable MI CABG IHD All Subjects
Diagnosis (%) 1,052 (44.2) 620 (26.1) 708 (29.7) 2,380
Demographic
Age at CRXT, yrs* 58.5  9.8 61.3  8.9 59.9  9.2 59.7  9.5
Body mass, kg 68.4  13.7 68.3  12.3 73.3  15.8 69.8  14.2
Body mass index, kg/m2 26.7  5.1 27.2  4.6 28.7  5.8 27.4  5.3
Clinical
Total cholesterol 240 mg/dl; 6.2 mmol/l; n (%) 250 (23.8) 164 (26.5) 178 (25.1) 592 (24.9)
History of hypertension (%) 31.6 29.4 30.2 30.6
Smoking, current (%) 16.5 5.1 13.1 12.5
History of smoking (%) 66.0 57.9 56.6 61.1
Diabetes (%) 8.7 15.8 9.4 10.8
Medication (%)
Platelet inhibitor 59.0 81.6 62.4 65.9
Beta-blocker 60.0 45.6 48.4 52.9
Nitrate 21.6 5.0 15.1 41.7
Calcium antagonist 29.2 18.2 55.6 34.2
Statin 5.5 7.1 6.7 19.3
Angiotensin-converting enzyme-inhibitor 6.8 3.6 3.8 14.2
Digoxin 7.5 14.2 3.4 8.0
Antiarrhythmic 5.1 2.7 1.4 3.4
Cardiorespiratory measurements
Resting values
Heart rate, beats/min 68.6  13.3 75.7  14.4 70.3  14.0 71.0  14.1
Blood pressure, mm Hg
Systolic 134.7  21.3 143.6  21.6 140.5  21.3 138.7  21.7
Diastolic 81.7  11.9 84.5  11.9 82.5  11.9 82.6  12.0
Peak Values
Heart rate, beats/min
Beta-blocked 111.2  19.4 110.5  19.3 108.4  17.6 110.3  19.0
Non–beta-blocked 132.3  18.2 135.0  18.3 134.0  19.8 133.7  18.8
Power output, W 79.3  26.5 73.7  23.2 88.0  27.9 80.4  26.6
Blood pressure, mm Hg
Systolic 176.4  25.1 188.2  24.5 185.0  26.8 182.1  25.9
Diastolic 91.1  12.7 93.4  13.2 90.2  12.8 91.4  12.9
VO2peak, ml/kg/min 15.4  4.0 14.0  3.3 15.6  4.0 15.1  3.9
Ventilatory threshold, ml/kg/min 11.1  2.3 10.7  2.1 11.4  2.3 11.1  2.2
Respiratory exchange ratio, U 1.1  0.1 1.1  0.1 1.1  0.1 1.1  0.1
BORG rating of perceived exertion, U 18.7  1.7 18.8  1.6 18.8  1.6 18.8  1.6
ST-segment depression 0.2 mV (%) 7.4 6.0 9.6 7.7
Exertional angina (%) 8.8 7.4 15.2 10.4
Ectopy at CRXT, Lown grade 3, 4, 5 (%) 9.5 12.3 5.6 9.1
Exertional hypotension (%)† 6.8 5.0 6.8 6.3
Values are mean  SD for continuous variables and n (%) for categorical variables. *CRXT indicates cardiorespiratory exercise test. †Exertional hypotension was defined as a
drop in systolic blood pressure below resting value or a failure to rise more than 10 mm Hg with two successive increases in power output (33.4 W).
CABG  coronary artery bypass graft; MI  myocardial infarction; IHD  ischemic heart disease; V˙O2peak  peak oxygen intake.
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The Kaplan-Meier curves for MI, CABG, and IHD
patients showed that the survival profiles for cardiac and
all-cause death were similar for the three diagnostic cate-
gories (log rank test, p  0.05) and, therefore, the data for
all three diagnoses were pooled.
Predictors of mortality. Univariate and multivariate anal-
yses of predictors of cardiac death are shown in Table 2.
Variables not achieving statistical significance on univariate
analysis were age, obesity (BMI 30 kg/m2), ST segment
depression 0.2 mV or anginal symptoms on test, exer-
tional ectopy (Lown 3, 4, or 5), current smoking or history
of smoking, hypercholesterolemia (total cholesterol 240
mg/dl, 6.2 mmol/l), exertional hypotension, and ventilatory
threshold, as well as taking aspirin, a beta-blocker, a calcium
antagonist, a nitrate, a statin, or an anticoagulant. Three of
the six variables achieving statistical significance after uni-
variate analysis remained on multivariate analysis. Taking a
V˙O2peak of 13 ml/kg/min ( 4 METs) as the referent,
values at or above this level conferred a 50% reduction in
cardiac death. When V˙O2peak was treated as a continuous
variable, for each 1.0 ml/kg/min advantage in V˙O2peak
subjects gained a 10% lower cardiac mortality (HR 0.90,
95% confidence interval [CI] 0.85 to 0.96, p  0.001)
within the range of the observed sample. Therapy with
antiarrhythmic drugs and a history of diabetes were signif-
icant adverse predictors of cardiac death.
Age did not emerge as a significant predictor of cardiac
death in the univariate analysis, and, therefore, we conclude
that the protective effect of a high V˙O2peak as well as the
adverse effects of antiarrhythmic therapy and of diabetes are
not influenced by age.
In terms of all-cause death, V˙O2peak values 13.0 ml/kg/
min conferred a 29% reduction in mortality, but because
almost one-half of the deaths were cardiac in origin, it
seemed likely that the association was heavily influenced by
this fact (Table 3).
We also considered the prognostic value of V˙O2peak
predicted from the peak power output on the cycle ergome-
ter (14). As we found in men (3), the predicted V˙O2peak
tended to overestimate aerobic power, with the result that in
21% of the total sample there was a discrepancy between
predicted and measured V˙O2peak. This differential discor-
dance between the predicted and the measured V˙O2peak
values was statistically significant (McNemar’s test p value
0.0001). In fact, at this cutoff, the agreement between the
predicted and measured values was moderate at best (kappa
coefficient  0.47, 95% CI 0.43 to 0.51).
Kaplan-Meier curves. The Kaplan-Meier survival curves
for cardiac and all-cause deaths are shown in Figure 1. When
data were grouped by initial V˙O2peak, there was a marked
protective effect with regard to cardiac death (Fig. 2) and for
all-cause death (Fig. 3) for those at or above V˙O2peak
13 ml/kg/min. Cardiac survival prospects were substantially
worsened by a history of diabetes (15-year survival: 64.4% vs.
88.2%, p  0.0001) and by antiarrhythmic therapy (15-year
survival: 71.4% vs. 87.6%, p  0.0001).
Table 2. Univariate and Multivariate Cox Proportional Hazards Model for Cardiac Death at
Entry to Study
Variable
Hazard
Ratio
Confidence
Interval p Value
Univariate
V˙O2peak, 13 ml/kg/min, referent 1.0 — —
V˙O2peak, 13 ml/kg/min 0.5 0.34–0.76 0.001
Antiarrhythmic therapy 3.4 1.87–6.3 0.0001
History of hypertension 1.7 1.09–2.5 0.017
Diabetes 3.0 1.72–5.13 0.0001
Angiotensin-converting enzyme inhibitors 2.2 1.1–4.4 0.025
Digoxin 2.1 1.25–3.57 0.005
Multivariate
V˙O2peak, 13 ml/kg/min, referent 1.0 — —
V˙O2peak, 13 ml/kg/min 0.5 0.38–0.80 0.001
Diabetes 2.7 1.55–4.82 0.0005
Antiarrhythmic therapy 3.9 2.3–7.21 0.0001
V˙O2peak  peak oxygen intake.
Table 3. Multivariate Proportional Hazards Model for All-Cause Death
Variable Hazard Ratio Confidence Interval p Value
V˙O2peak, 13 ml/kg/min, referent 1.00 — —
V˙O2peak, 13 ml/kg/min 0.71 0.53–0.95 0.0204
History of hypertension 1.52 1.14–2.04 0.0042
Diabetes 1.99 1.29–3.07 0.0019
Antiarrhythmic therapy 2.13 1.30–3.51 0.0027
Digoxin 1.47 1.00–2.16 0.0493
V˙O2peak  peak oxygen intake.
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DISCUSSION
Our data demonstrate that, as in men, the prognosis of
women with coronary artery disease is strongly linked to
their exercise capacity, and this observation is in keeping
with prior work (5,6,8). Using techniques identical to those
we had previously used in men (3), we found that the
magnitude of the advantage of well-conserved aerobic func-
tion is relatively independent of gender. Thus, the V˙O2peak
cutoff point above which there is a marked benefit in
prognosis (13 ml/kg/min in women versus 15 ml/kg/min in
men), as well as the 1 ml/kg/min advantage in V˙O2peak
when treated as a continuous variable (10% lowering of
cardiac mortality in women versus 9% in men), is similar to
that we had previously noted in men (3).
Other significant multivariate predictors in our analysis
were diabetes and antiarrhythmic therapy (for cardiac
deaths), and a history of hypertension, diabetes, or anti-
arrhythmic or digoxin therapy (for all-cause deaths). The
increase in risk associated with the taking of an antiarrhyth-
mic drug is likely due to the fact that 40% of these patients
were taking proarrhythmic agents (quinidine, disopyramide,
procainamide), which were commonly prescribed in the
early years of the follow-up period.
Exercise-induced ST-segment depression is less sensitive
in women than in men (15,16), and, therefore, it is not
surprising that in our data this variable was not a significant
predictor of death.
Study limitations. Our conclusions are based on relatively
young women (70 years) with stable CHD who were
referred for cardiac rehabilitation, and may not apply across
the spectrum. No patients were in overt heart failure, and
severe comorbidities such as peripheral vascular disease,
chronic pulmonary disease, and disabling arthritis were rare.
Also, our sample contained few subjects from ethnic minor-
ity groups, being predominantly white and from the middle
classes. Finally, secular trends in behavior and environmen-
tal factors, inevitable in a long follow-up, as well as shifts in
clinical practice, may have influenced the shape of the
mortality curves.
Conclusions. From a clinical viewpoint, in men as in
women with proven coronary artery disease, measured
V˙O2peak is a strong independent guide to prognosis, is not
influenced by age, and is more valid than a predicted
V˙O2peak.
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Figure 1. Kaplan-Meier survival curves for cardiac and all-cause deaths.
Figure 2. Kaplan-Meier survival curves for cardiac deaths by peak oxygen
intake (V˙O2peak) categorized at, or above, or below 13 ml/kg/min.
Figure 3. Kaplan-Meier survival curves for all-cause deaths by peak oxygen
intake (V˙O2peak) categorized at, or above, or below 13 ml/kg/min.
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